The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Dextroamphetamine is also a full agonist of trace amine-associated receptor 1 (TAAR1), a G-protein coupled receptor that regulates monoaminergic systems in the brain; activation of TAAR1 may restore impaired dopaminergic signaling in the prefrontal cortex and thereby correct deficits in inhibitory control associated with binge eating behaviors. Alongside its effect on cognitive control, appetite suppression is a common side effect of lisdexamfetamine and is associated with reduced food intake. Amphetamines are believed to dampen the sensation of hunger through actions in the lateral hypothalamus; this is thought to involve increased catecholaminergic signaling and the induction of cocaine- and amphetamine-regulated transcript (CART), a hypothalamic neuropeptide involved the regulation of food intake. While appetite suppression may influence the magnitude of reductions in food intake, three medical reviews indicate that lisdexamfetamine's enhancement of cognitive control is the primary therapeutic effect for reducing binge-eating symptoms and is likely required for addressing the disorder's underlying psychopathology. This view is supported by the failure of anti-obesity medications and other appetite suppressants to significantly reduce BED symptom severity, despite their ability to produce weight loss. Medical reviews of randomized controlled trials have demonstrated that lisdexamfetamine, at doses between 50–70 mg, is safe and effective for the treatment of moderate-to-severe BED in adults.
Atmoun in 2019 brokered a deal between Morocco's foreign intelligence agency, Direction générale des études et de la documentation (DGED) and Panzeri and his colleague Francesco Giorgi, whereby the two would each receive €50,000 a year for lobbying on behalf of Morocco. Marie Arena, head of the subcommittee on human rights comes into the Morocco scene, Atmoun invited Arena and Panzeri to Morocco in January 2022. Giorgi reported that he and Panzeri billed Atmoun for ensuring that mentions of Morocco vanished from a Parliament report on human rights violations. Later in 2022 Arena's son, Ugo Lemaire went on a trip to Morocco, paid for by a Moroccan company. Andrea Cozzolino also appears in the Morocco investigation, he was part of the committee investigating Morocco's use of spyware and was chair of the Parliament's Maghreb delegation coordinating the EU interaction with North African countries. Cozzolino and Atmoun met with Morocco's DGED in Warsaw. In September 2022, 4 Brussels MPs – David Leisterh, David Weytsman, Clémentine Barzin, and Gaëtan Van Goidsenhoven – visited the city of Laâyoune in Western Sahara. The Moroccan parliament had invited the MEPs and paid for the entire trip. Western Sahara is a disputed region, which Morocco claims to be its own. However, after the Belgium investigation opened, the MEPs' trip came under greater scrutiny.
=== Pharmacokinetics === Desloratadine is well absorbed from the gut and reaches highest blood plasma concentrations after about three hours. In the bloodstream, 83 to 87% of the substance are bound to plasma proteins. Desloratadine is metabolized to 3-hydroxydesloratadine in a three-step sequence in normal metabolizers. First, N-glucuronidation of desloratadine by UGT2B10; then, 3-hydroxylation of desloratadine N-glucuronide by CYP2C8; and finally, a non-enzymatic deconjugation of 3-hydroxydesloratadine N-glucuronide. Both desloratadine and 3-hydroxydesloratadine are eliminated via urine and feces with a half-life of 27 hours in normal metabolizers.
Sources: en.wikipedia.org
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Isotopic compositions and standard atomic masses from: de Laeter, John Robert; Böhlke, John Karl; De Bièvre, Paul; Hidaka, Hiroshi; Peiser, H. Steffen; Rosman, Kevin J. R.; Taylor, Philip D. P. (2003). "Atomic weights of the elements. Review 2000 (IUPAC Technical Report)". Pure and Applied Chemistry. 75 (6): 683–800. doi:10.1351/pac200375060683. Wieser, Michael E. (2006). "Atomic weights of the elements 2005 (IUPAC Technical Report)". Pure and Applied Chemistry. 78 (11): 2051–2066. doi:10.1351/pac200678112051. "News & Notices: Standard Atomic Weights Revised". International Union of Pure and Applied Chemistry. 19 October 2005. Half-life, spin, and isomer data selected from the following sources. G. Audi; A. H. Wapstra; C. Thibault; J. Blachot; O. Bersillon (2003). "The NUBASE evaluation of nuclear and decay properties" (PDF). Nuclear Physics A. 729 (1): 3–128. Bibcode:2003NuPhA.729....3A. doi:10.1016/j.nuclphysa.2003.11.001. Archived from the original (PDF) on 2011-07-20. National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
=== Cancer === In response to a report of precancerous changes in the pancreases of rats and organ donors treated with the DPP-4 inhibitor sitagliptin, the US FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-4 inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicine, the agencies stated that they had not yet reached a final conclusion regarding a possible causative relationship. A 2014 meta-analysis found no evidence for increased pancreatic cancer risk in people treated with DPP-4 inhibitors, but owing to the modest amount of data available, the authors were unable to completely exclude possibly increased risk.
=== Russia === Russian authorities stated that Russia reacted to the numerous casualties among the South Ossetian civilian population caused by the Georgian attack. According to Russia, its aim was defence of Russian citizens and Russian peacekeepers in South Ossetia. According to the Russian military, the Russian peacekeepers in South Ossetia suffered casualties on August 8. Initially, Russia went as far as accusing Georgia of committing "genocide" against Ossetians. Defending Russia's decision to launch attack in uncontested Georgia, Russian Foreign Minister Sergey Lavrov said that Russian targeting of military infrastructure used for the Georgian attack was legally warranted. It was claimed that Georgia codenamed its attack Operation "Clear Field". Russia also claimed that Georgia was planning to launch a two-day Operation "Rock" to retake Abkhazia. Russia codenamed its military action "Operation to Force Georgia to Peace". The term "enforcing to peace" for describing the war against Georgia allegedly has been coined by General Anatoliy Nogovitsyn. Three years after the August War, President of Russia Dmitry Medvedev stated that NATO would have admitted Post-Soviet states if Russia had not invaded Georgia. "If you...had faltered back in 2008, the geopolitical situation would be different now," Medvedev declared at a Vladikavkaz military base. In response, the Georgian authorities claimed that Medvedev had admitted that Russia started the war with Georgia.
Sources: en.wikipedia.org
Sunak later announces that the UK will send Ukraine hundreds of air defence missiles and armed drones, in addition to the Storm Shadow cruise missiles previously promised. 16 May Following a trial at Reading Crown Court, three fraudsters who supplied forged passports to some of the UK's most notorious criminals, are sentenced to prison. Data produced by the Office for National Statistics indicates the number of people not working because of a long-term health condition has reached two and a half million. The rise is attributed to an increase in mental health problems among young people, and an increase in people suffering back and neck problems as a result of working at home. Stellantis, owners of Vauxhall, Peugeot, Citroen and Fiat, urge the UK government to renegotiate parts of its Brexit trade deal, warning that the UK could lose its car industry. The company has committed to making electric vehicles in the UK, but says it may not be able to do so because of the combined effect of post-Brexit trade rules and increases in raw material costs. 17 May The Renters (Reform) Bill is introduced into Parliament. The UK government bans the issuing of licences for animal testing of chemicals used in cosmetics products. 18 May 2023 Northern Ireland local elections: Local elections are held in Northern Ireland, two weeks after the rest of the country. Figures released by HM Treasury indicate the funeral of Elizabeth II and associated events cost the UK government £162m. 19 May John Allan announces he is stepping down as chairman of Tesco following allegations over his conduct.
=== Antibody-free protein detection === While protein detection with antibodies is still very common in molecular biology, other methods have been developed as well, that do not rely on an antibody. These methods offer various advantages, for instance they often are able to determine the sequence of a protein or peptide, they may have higher throughput than antibody-based, and they sometimes can identify and quantify proteins for which no antibody exists.
=== Radiation protection register === According to § 170 StrlSchG [Radiation Protection Act] (in German) all occupationally exposed persons and holders of radiation passports require a radiation protection register number (SSR number or SSRN), a unique personal identification number, as of December 31, 2018. The SSR number facilitates and improves the allocation and balancing of individual dose values from occupational radiation exposure in the radiation protection register. It replaces the former radiation passport number. It is used to monitor dose limits. Companies are obliged to deploy their employees in such a way that the radiation dose to which they are exposed does not exceed the limit of 20 millisieverts per calendar year. In Germany, about 440,000 people were classified as occupationally exposed to radiation in 2016. According to § 145 StrlSchG [German Radiation Protection Act] (in German) paragraph 1, Sentence 1, "in the case of remediation and other measures to prevent and reduce exposure at radioactively contaminated sites, the person who carries out the measures himself or has them carried out by workers under his supervision must carry out an assessment of the body dose of the workers before starting the measures". Applications for SSR numbers must be submitted to the Federal Office for Radiation Protection (BfS) by March 31, 2019 for all employees currently under surveillance.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.